Trial Profile
A prospective randomized study to compare the cumulative achievement of complete molecular response for adult de novo chronic myeloid leukemia in chronic phase between nilotinib and dasatinib
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Jan 2021
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms CML212; JALSG CML212
- 08 Dec 2020 Status changed from active, no longer recruiting to completed, as per Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
- 19 Oct 2016 Status changed from not yet recruiting to active, no longer recruiting.